北陆药业获得碘美普尔注射液药品注册证书

Core Viewpoint - Beilu Pharmaceutical (300016.SZ) has received approval from the National Medical Products Administration for the iodine-based contrast agent, Iodine Meper, which is expected to drive significant sales growth in the coming years [1] Group 1: Product Details - Iodine Meper is a non-ionic monomer X-ray contrast agent developed by Italy's Bracco, characterized by excellent physicochemical properties, including the lowest osmotic pressure and lower viscosity compared to similar agents at the same concentration [1] - The product is stable in its physicochemical properties and does not require the addition of chelating agents [1] - Indications for Iodine Meper include intravenous urography, CT scans, conventional angiography, and various forms of vascular imaging for both adults and children [1] Group 2: Market Potential - Iodine Meper has been included in the National Medical Insurance Class B directory, enhancing its market accessibility [1] - According to data from Minet, sales in China's three major terminal markets have been growing at double-digit rates, with projected sales exceeding 1.1 billion yuan in 2024, representing a year-on-year growth of approximately 32% [1] - In the first quarter of 2025, sales are expected to surpass 300 million yuan, with a year-on-year growth of about 39% [1]